Month: July 2024
Using qPCR for single-nucleotide Polymorphisms (SNP)
Single-nucleotide polymorphisms (SNPs) are the most prevalent genetic variations among people. Each SNP signifies a variation in a single DNA building block known as a nucleotide. Detecting these SNPs is crucial, and it’s the cornerstone of our understanding of genetic diversity, disease susceptibility, and drug response in genetic research. One of the most potent and…
Cell-Based Assays Using Thawed PBMCs: A Usable Specific Process.
Cell-based assays are a cornerstone of immunological research, providing invaluable insights into cellular behavior and function. One of the most used cell types in these assays is Peripheral Blood Mononuclear Cells (PBMCs). These cells, which include lymphocytes (T cells, B cells, and NK cells) and monocytes, play crucial roles in our immune response. Thawed PBMCs…
DPCR for Viral Titrations and VCN: Rely on Sword Bio’s Unique Expertise
In molecular biology, Polymerase Chain Reaction (PCR) has revolutionized how we study and quantify nucleic acids. Two prominent techniques, Quantitative PCR (qPCR) and Digital PCR (dPCR), have emerged as powerful tools for sensitive and specific detection. While both technologies have their strengths, this blog post will focus on the advantages of dPCR over qPCR for viral titration and vector…
Modifications and challenges for Bispecific Antibodies and the potential solutions for developing PK assays
Antibody-based therapeutics are evolving from monoclonal antibodies to antibody derivatives with complex structures to achieve advanced therapeutic effects. The complexity of Bispecific Antibodies (bsAbs) is due to the antibodies’ containing two different binding domains, which allow them to simultaneously target two distinct antigens. Understanding their pharmacokinetics (PK) requires a sophisticated bioanalytical approach to characterize the…
ADA Assay Considerations: Rely on Sword Bio’s Unparalleled Expertise
The Positive Control (PC) reagent is pivotal when embarking on a new anti-drug antibody (ADA) assay. Regulatory agencies typically favor polyclonal PCs because they represent the in vivo immunological response. While they have accepted monoclonal PCs, they often inquire about the rationale behind this choice. For straightforward biotherapeutics, a simple explanation suffices. However, as the complexity…